Feb 17, 2026 08:30AM
Jan 22, 2026 06:49AM
Jan 21, 2026 06:20AM
Jan 6, 2026 01:37PM
Dec 29, 2025 08:00AM
Dec 29, 2025 08:00AM
Nov 24, 2025 08:30AM Biotech Valuations Rise as New Clinical Platforms Show Progress
Nov 17, 2025 06:07PM
Nov 17, 2025 08:14AM
Nov 17, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 6, 2025 07:30AM
Nov 6, 2025 07:30AM
Nov 6, 2025 07:30AM FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Oct 14, 2025 06:26AM
Oct 14, 2025 06:22AM
Oct 14, 2025 06:21AM
Oct 14, 2025 06:20AM
Oct 13, 2025 05:04AM
Oct 10, 2025 04:20PM
Oct 10, 2025 11:27AM Protagonist Therapeutics stock surges after J&J acquisition talks report
Sep 25, 2025 04:15PM
Sep 25, 2025 04:15PM
Jul 16, 2025 06:20AM
Jun 30, 2025 06:45AM
May 22, 2025 03:03AM
Apr 15, 2025 06:20AM
Apr 15, 2025 04:00AM Analysts brace for volatile Johnson & Johnson Q1 amid Part D impact, legal setbacks
Apr 2, 2025 08:45AM
Apr 2, 2025 08:44AM
Apr 1, 2025 04:07PM
Apr 1, 2025 04:06PM
Mar 25, 2025 01:11PM
Feb 15, 2025 10:00PM
Feb 3, 2025 07:10AM Johnson & Johnson (JNJ) PT Raised to $166 at Guggenheim
Jan 22, 2025 06:23AM
Jan 22, 2025 06:20AM
Jan 13, 2025 09:54AM
Jan 13, 2025 06:32AM
Jan 13, 2025 06:30AM
Oct 15, 2024 07:04AM
Oct 15, 2024 06:20AM Johnson & Johnson Reports Q3 2024 Results
Oct 15, 2024 03:00AM
Oct 10, 2024 07:34AM
Oct 9, 2024 08:01AM
Oct 9, 2024 08:00AM
Oct 4, 2024 08:52AM
Sep 4, 2024 11:00AM
Aug 29, 2024 08:00AM Johnson & Johnson (JNJ) seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Aug 29, 2024 08:00AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All